Clinical Trial Update: A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic interaction study of the Hedgehog pathway inhibitor GDC-0449 with rosiglitazone or with a combined oral contraceptive in patients with l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Solid Tumors

Drugs mentioned

• Combined oral contraceptive
• GDC-0449 (vismodegib)
• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Genentech, Inc. | Conditions: Solid Cancers | Phase 1 | Status: COMPLETED | Results posted: 2015-06-29